Table 1. Percentages of lymphocyte subsets after Tofa treatment.
| CD3 | CD4 | CD8 | CD4/CD8 ratio | CD19 | CD16/56 | ||
| day 0 | 70.4±6.2 | 63.2±8.3 | 29.0±6.1 | 2.3±0.7 | 7.5±3.1 | 17.1±10.0 | |
| day 4 | NS Tofa0 | 76.9±8.3 | 58.4±12.5 | 31.4±6.5 | 2.0±0.9 | 5.7±2.3 | 12.3±7.6 |
| NS Tofa10 | 80.6±5.0 | 60.8±12.2 | 29.4±5.7 | 2.2±0.7 | 5.5±2.3 | 9.6±4.2 | |
| NS Tofa100 | 87.6±3.8 | 52.3±23.8 | 25.7±9.7 | 2.6±2.0 | 1.9±0.8 | 3.6±1.8 | |
| PHA Tofa0 | 85.8±6.6 | 58.0±10.3 | 33.0±7.5 | 1.9±0.6 | 3.9±2.1 | 4.6±2.3 | |
| PHA Tofa10 | 83.5±7.4 | 68.7±9.2 | 23.6±7.3 | 3.2±1.1 | 2.0±1.1 | 3.1±1.5 | |
| PHA Tofa100 | 84.8±9.1 | 50.2±21.4 | 29.9±5.3 | 1.8±1.0 | 1.7±0.7 | 3.0±2.5 | |
| day 4+4 | NS Tofa0 | 85.5±1.5 | 61.0±8.6 | 30.4±4.6 | 2.1±0.6 | 5.0±2.3 | 2.1±1.3 |
| NS Tofa10 | 86.1±7.9 | 63.0±9.5 | 25.7±8.0 | 2.7±1.0 | 4.0±2.0 | 1.2±0.5 | |
| NS Tofa100 | 82.0±11.4 | 60.5±15.7 | 21.4±9.9 | 3.6±2.2 | 2.3±0.8 | 0.6±0.4 | |
| PHA Tofa0 | 87.7±1.1 | 50.1±5.9 | 43.5±4.0 | 1.2±0.2 | 3.5±0.6 | 5.1±1.7 | |
| PHA Tofa10 | 94.6±1.6 | 75.5±7.4 | 22.4±6.9 | 3.7±1.3 | 1.3±0.5 | 0.1±0.0 | |
| PHA Tofa100 | 91.7±4.0 | 73.5±9.7 | 22.9±9.7 | 3.7±1.6 | 0.9±0.3 | 0.2±0.1 |
Cells were analysed before treatment (day 0), after 4 days of incubation with Tofa (day 4) and then four days after the withdrawal of the drug (day 4+4). Percentage of CD3, CD19 and CD16/56 cells were evaluated on total lymphocytes, while CD4 cells, CD8 cells and CD4/CD8 ratio was evaluated on CD3 positive T lymphocytes. Data are expressed as mean ± SD of four independent experiments.